

Hyaluronic Acid Derivative (HAD) for Joint Fluid Replacement
Durolane; Euflexxa; Gel-One; Gelsyn-3; GenVisc; Hyalgan; Hymovis; Monovisc;
OrthoVisc; Synjoynt; Supartz; Synvisc; Synvisc One; Triluron; TriVisc; Visco-3
Effective 04/01/2023

Plan	<input checked="" type="checkbox"/> MassHealth UPPL <input type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input checked="" type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input type="checkbox"/> Pharmacy Benefit <input checked="" type="checkbox"/> Medical Benefit (NLX)		
Specialty Limitations			
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions			

Overview

Hyaluronic Acid Derivatives are used in the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed nonpharmacologic treatment and conventional analgesics

Coverage Guidelines

Members may be approved for a Hyaluronic Acid Derivative if ALL the following criteria has been met and documentation has been provided:

1. The Member has a documented diagnosis of knee osteoarthritis
2. Paid claims or physician attestation of inadequate response to a 30 day trial, adverse reaction or contraindication to acetaminophen
3. **ONE** of the following:
 - a. Physician attestation of inadequate response or adverse reaction to intra-articular corticosteroid injection
 - b. Contraindication to all intra-articular corticosteroid injections
4. **ONE** of the following:
 - a. Paid claims within last 90 days or physician attestation of inadequate response to a 30 day trial or adverse reaction to one NSAID
 - b. Contraindication to all NSAIDs

Continuation of Therapy

Reauthorizations beyond 6 months of initial request is sufficient for response to therapy.

Limitations

1. Initial approvals and reauthorizations will be granted for 6 months.
- 3 The plan does not cover hyaluronic acid derivatives for the treatment of osteoarthritis in locations other than the knee because it is considered experimental, investigational, or unproven.
- 4 The plan does not cover hyaluronic acid derivatives for the treatment of isolated patella femoral arthritis or patella femoral syndrome as this is considered experimental, investigational, or unproven

References

1. Euflexxa [prescribing information]. Parsippany, NJ: Ferring Pharmaceuticals Inc; August 2011.
2. Hyalgan (hyaluronic acid derivative) [prescribing information]. Parsippany, NJ: Fidia Pharma; May 2014
3. Orthovisc [prescribing information]. Raynham, MA: Anika Therapeutics; June 2005.
4. Supartz [prescribing information]. Durham, NC: Bioventus; June 2012.
5. Synvisc (hylan G-F 20) [prescribing information]. Ridgefield, NJ: Genzyme Biosurgery a division of Genzyme Corporation; September 2014
6. Synvisc-One [prescribing information]. Ridgefield, NJ: Genzyme Corp; January 2010.
7. Gel-One [prescribing information]. Warsaw, IN: Zimmer; May 2011.
8. Monovisc [prescribing information]. Bedford, MA: Anika Therapeutics; December 2013.
9. Supartz FX (sodium hyaluronate) [prescribing information]. Durham, NC: Bioventus; April 2015.
10. GenVisc 850 (sodium hyaluronate) [prescribing information]. Doylestown, PA: OrthogenRx Inc; received September 2015
11. Bannuru RR, Schmid CH, Kent DM, Vaysbrot EE, Wong JB, McAlindon TE. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: A systematic review and network meta-analysis. *Ann Intern Med.* 2015;162(1):46-54
12. Fransen M, McConnell S, Harmer AR, et al. Exercise for osteoarthritis of the knee: a Cochrane systematic review. *Br J Sports Med* 2015; 49:1554
13. Nelson AE, Allen KD, Golightly YM, et al. A systematic review of recommendations and guidelines for the management of osteoarthritis: The chronic osteoarthritis management initiative of the U.S. bone and joint initiative. *Semin Arthritis Rheum* 2014; 43:701
14. Messier SP, Mihalko SL, Legault C, et al. Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: the IDEA randomized clinical trial. *JAMA* 2013; 310:1263

Review History

06/19/2019 – Reviewed

05/20/2020 – Reviewed May P&T Mtg; References updated; added all medications to ‘Limitations’

7/22/2020 – Updated July P&T Mtg; added Triluron to criteria. Effective 8/1/20

07/21/2021- Added Kellgren scale requirement, added additional reauth criteria; added coverage restriction of diagnosis of isolated patella femoral arthritis or patella femoral syndrome as this is considered experimental, investigational or unproven; approval time to 2 months. Effective 10/01/2021.

03/16/2022 – Reviewed and Updated for March P&T; Administrative update to include preferred products into criteria. No clinical change.

09/21/2022 – Reviewed at Sept P&T; Separated Comm/Exch vs MH policy; no clinical updates

03/15/23 - Reviewed and updated for Mar P&T. Matched MH UPPL criteria. Effective 4/1/23.

